CME Presentations

TH2-driven Conditions


Presentations


Speakers

  • John Bosso, MD

    John Bosso, MD

    John Bosso, MD

    Clinical Profressor, Division of Rhinology

    John V. Bosso, MD, serves as medical director of the Aspirin Exacerbated Respiratory Disease (AERD or Samter’s triad) Center and director of the OTO-Allergy Clinic at Penn Medicine in Philadelphia. He is one of the country’s most experienced AERD super-specialists with over 30 years of expertise in managing this challenging condition. Dr Bosso was one of the first allergy/immunology fellows to learn the techniques of aspirin desensitization and has subsequently successfully desensitized over 1000 AERD patients. His current research focuses on potential causes, molecular mechanisms, and treatments of AERD. Dr Bosso has spoken at national otorhinolaryngology meetings and served on AERD panels. In addition, he is a proud supporter of the Samter’s Society, a support group for AERD sufferers.
  • Zachary Soler, MD, MSc

    Zachary Soler, MD, MSc

    Zachary Soler, MD, MSc

    Associate Professor of Otolaryngology Head Neck Surgery

    Zachary M. Soler, MD, MSc, is an associate professor in the Department of Otolaryngology-Head and Neck Surgery at the Medical University of South Carolina in Charleston. His clinical and surgical practice focuses on patients with refractory chronic rhinosinusitis. Dr Soler is the principal investigator of a multi-center NIH study that explores outcomes in patients with chronic rhinosinusitis. He has authored over 180 peer-reviewed publications related to rhinology.
  • Sanaz Eftekhari

    Sanaz Eftekhari

    Sanaz Eftekhari

    Vice President of Corporate Affairs and Research

    Sanaz Eftekhar, vice president of Corporate Affairs and Research at AAFA, leads tactical and strategic conversations with business partners and stakeholders across multiple industries. She has been instrumental in working with AAFA’s partners to present patient perspectives on the needs for atopic dermatitis treatments to the US Food and Drug Administration. In a greater effort to connect patients with vital clinical trials, Sanaz has been a key player in the development of AAFA’s upcoming clinical trial database. She has led AAFA’s involvement in the CIU & You campaign since its launch in 2015, co-authored several key AAFA research reports, and serves as secretary on the Board of Directors for the Global Allergy & Airways Patient Platform (GAAPP).
  • Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI

    Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI

    Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI

    Head of Toronto Allergists

    Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI, is a practicing physician specializing in immunotherapy treatment of allergic diseases, including allergic asthma, at Toronto Allergists in Toronto, ON, Canada. In addition, he is a clinical director and managing partner at Toronto Allergists as well. Furthermore, Dr. Lee is the CEO of Evidence Based Medical Educator Inc. in Toronto and the founder and chair of Urticaria Canada. Dr. Lee earned a Doctor of Medicine degree from the Faculty of Medicine at the University of Toronto. He received fellowship training in internal medicine at the University of British Columbia in Vancouver, Canada, and in clinical immunology and allergy at the University of Toronto. He was the past head of asthma at the Canadian Society for Allergy and Clinical Immunology.
  • Kenneth Mendez

    Kenneth Mendez

    Kenneth Mendez

    CEO and President

    Kenneth Mendez is the CEO and President of the Asthma and Allergy Foundation of America (AAFA). Since joining AAFA, he has led the organization in establishing a new multi-year strategic plan that emphasizes reducing the impact of asthma and allergies on the underserved and tripling the size of AAFA’s online asthma community. The new strategic plan’s vision is for AAFA to be recognized as the most trusted ally serving the asthma and allergy community. He served as an External Reviewer for the Institute for Clinical and Economic Review’s (ICER) asthma assessment and patient advocacy expert for ICER’s review on emerging peanut allergy therapies. In addition, he leads communications with the US Department of Health and Human Services on ongoing access barriers to epinephrine auto-injectors.
  • David M. Lang, MD

    David M. Lang, MD

    David M. Lang, MD

    Professor of Medicine

    David Lang, MD, is a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. Dr. Lang served as President of the American Academy of Allergy, Asthma and Immunology from 2019-2020. He has chaired or served on numerous committees/task forces, formerly served as Co-Chair of the Joint Task Force on Practice Parameters and was a member of this Task Force from 2001-2018. He currently serves on the Primary Care and Chronic Illness Standing Committee at the National Quality Forum, and previously was Co-Chair of the Pulmonary and Critical Care Standing Committee. Dr. Lang has carried out a number of research projects, including studies of aspirin exacerbated respiratory disease, asthma, anaphylaxis, drug allergy, and urticaria

CME Information

Moving Toward a Targeted Approach for Nasal Polyps

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the Asthma and Allergy Foundation of America (AAFA).

This activity is supported by an independent medical education grant from OptiNose US Inc, Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Friday, July 30, 2021 from 3:00 – 4:00pm ET

Enduring Material

The enduring material will be available from July 30, 2021 to July 30, 2022.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Summarize the disease burden experienced by patients with NPs
  • List the limitations of traditional interventions for NPs, including oral or nasal steroids, antibiotics, and surgery
  • Explain the rationale for locally and immunologically targeted approaches to NP management
  • Summarize the efficacy and safety of new and emerging therapies with new mechanisms of action and/or modes of administration for people with NPs

TARGET AUDIENCE

The intended audience for this activity are otorhinolaryngologists (ORLs), allergists, primary care physicians, advanced practitioners (nurse practitioners and physician assistants), and nurses.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
John V. Bosso, MD
Clinical Professor
Division of Rhinology
Deptartment of Otorhinolaryngology: Head and Neck Surgery
University of Pennsylvania
Perelman School of Medicine
Consulting Fees (e.g., advisory boards): GSK, Novartis, Sanofi-Regeneron, AstraZeneca
Contracted Research: OptiNose US Inc
Sanaz Eftekhari
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America
Nothing to disclose
Zachary M. Soler, MD, MSc
Associate Professor of Otolaryngology Head Neck Surgery
Medical University of South Carolina
Consulting Fees (e.g., advisory boards): GSK, Lyra, Novartis, OptiNose US Inc, Sinusonic

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@ImmunologyLive.com.

Chronic Spontaneous Urticaria: New Hope with Emerging Targeted Agents

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the Asthma and Allergy Foundation of America (AAFA).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

Postgraduate Institute for Medicine designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Friday, September 24, 2021, at 2:00-3:00pm EST

Enduring Material

September 24, 2021 – September 24, 2022.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Account for high disease burden resulting from delays in diagnoses and multiple treatment failures experienced by many CSU patients when making therapeutic decisions.
  • Explain the limitations of current management of CSU with second-generation H1-antihistamine and anti-IgE agents, even when used at their maximal, guideline-recommended doses for CSU.
  • Describe how agents that block interleukin signaling involved in T2 inflammation pathways may provide an alternative to omalizumab for patients who are symptomatic despite use of H1 antihistamines or who are naïve to, intolerant of, or incomplete responders to omalizumab.
  • Summarize the anticipated place of emerging agents targeting T2 inflammation in the treatment of CSU.

TARGET AUDIENCE

The intended audience dermatologists, allergists, specialty nurse practitioners, and specialty physician assistants.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
David M. Lang, MD
Professor of Medicine
Chair, Department of Allergy & Clinical Immunology
Cleveland Clinic
Consulting Fees: AstraZeneca Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: AstraZeneca, Sanofi-Regeneron Contracted Research: Genentech, Gilead, NIAID, Novartis, Regeneron
Jason K. Lee, MD, FRCPC, FAAAAI, FACAAI
Past Head of Asthma, Canadian Society of Allergy & Clinical Immunology
Head of Toronto Allergists, Toronto Allergy and Asthma Clinic
CEO of Evidence Based Medical Educator Inc.
Consulting Fees: Abbvie, AstraZeneca, GSK, Novartis, Pfizer, Regeneron, Sanofi, Takeda Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: AstraZeneca, GSK, Merck, Mylan, Novartis, Pfizer, Regeneron, Sanofi, Takeda Contracted Research: AstraZeneca, Genentch, GSK, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda
Kenneth Mendez, MBA
President and CEO
Asthma and Allergy Foundation of America
Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact ImmunologyLive.com at 1-877-394-1306 or at Support@ImmunologyLive.com.